0000930413-17-001060.txt : 20170316 0000930413-17-001060.hdr.sgml : 20170316 20170316141755 ACCESSION NUMBER: 0000930413-17-001060 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20170316 DATE AS OF CHANGE: 20170316 EFFECTIVENESS DATE: 20170316 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-03619 FILM NUMBER: 17693963 BUSINESS ADDRESS: STREET 1: 235 E 42ND ST CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 2125732323 MAIL ADDRESS: STREET 1: 235 E 42ND ST CITY: NEW YORK STATE: NY ZIP: 10017 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 DEFA14A 1 c87736_defa14a.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934 (Amendment No.       )

Filed by the Registrant   [X]
Filed by a Party other than the Registrant   [_]

Check the appropriate box:

[_] Preliminary Proxy Statement
[_] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (as permitted by Rule 14a-6(e)(2))
[_] Definitive Proxy Statement
[X] Definitive Additional Materials
[_] Soliciting Material Pursuant to Section 240.14a-12


Pfizer Inc.


(Name of Registrant as Specified In Its Charter)
 

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

[X] No fee required.
 
[_] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 
1) Title of each class of securities to which transaction applies:
   

2) Aggregate number of securities to which transaction applies:
   

3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
   

4) Proposed maximum aggregate value of transaction:
   
 
5) Total fee paid:
   
[_] Fee paid previously with preliminary materials:
   
[_]  Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.
   
  1) Amount previously paid:
 

  2) Form, Schedule or Registration Statement No.: 
 

  3) Filing Party: 
 

  4) Date Filed:
     


 

    

 

    Vote by Internet
    •  Go to www.investorvote.com/PFE; or
    •  Scan the QR code with your smartphone.
    •  Follow the steps outlined on the secure website.

 

Annual Meeting Notice & Admission Ticket 

 

Important Notice Regarding the Availability of Proxy Materials for the
2017 Annual Meeting of Pfizer Inc. Shareholders to be held on April 27, 2017

 

Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual meeting are available on the Internet or by mail. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important!

 

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. These materials are available at:

 

www.investorvote.com/PFE

 

 Easy Online Access — A Convenient Way to View Proxy Materials and Vote.
 When you go online to view materials, you can also vote your shares.
 Step 1: Go to www.investorvote.com/PFE.
 Step 2: Click on the icon on the right to view current meeting materials.
 Step 3: Return to the investorvote.com window and follow the instructions on the screen to log in.
 Step 4: Make your selection as instructed on each screen to select delivery preferences and vote.

 

When you go online, you can also help the environment by consenting to receive electronic delivery of future materials.

 

 

 Obtaining a Copy of the Proxy Materials - If you want to receive a copy of these documents, you must request one. There is no charge to you for requesting a copy. Please make your request for a copy as instructed on the reverse side on or before April 18, 2017 to facilitate timely delivery.

 

 02IDOG 
 
Annual Meeting Notice & Admission Ticket  

 

2017 Annual Meeting of Pfizer Inc. Shareholders

 

Thursday, April 27, 2017
9:00 a.m., Eastern Daylight Time
Hilton Short Hills Hotel
41 John F. Kennedy Parkway
Short Hills, New Jersey 07078

 

Shareholders will be admitted to the Annual Meeting beginning at 8:30 a.m., Eastern Daylight Time. If you wish to attend,
please plan to arrive early since seating will be limited. For directions, contact the Hilton Short Hills Hotel at +1-973-379-0100.

 

PLEASE NOTE - YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares, you must vote online or request a paper copy of the proxy materials to receive a proxy card. If you wish to attend and vote at the meeting, please bring this notice with you.

 

The proposals to be voted on at the meeting, and the recommendations of the Board of Directors, are listed below.

 

The Board of Directors recommends a vote “FOR” the following proposals:

  1.Election of Directors:
   Dennis A. Ausiello, Ronald E. Blaylock, W. Don Cornwell, Joseph J. Echevarria, Frances D. Fergusson, Helen H. Hobbs, James M. Kilts, Shantanu Narayen, Suzanne Nora Johnson, Ian C. Read, Stephen W. Sanger, James C. Smith
  2.Ratify the selection of KPMG LLP as independent registered public accounting firm for 2017
  3.Advisory approval of executive compensation
    
The Board of Directors recommends you vote for “1 YEAR” on the following proposal:
  4.Advisory vote on the frequency of future advisory votes on executive compensation
    
The Board of Directors recommends a vote “AGAINST” the following proposals:
  5.Shareholder proposal regarding The Holy Land Principles
  6.Shareholder proposal regarding special shareowner meetings
  7.Shareholder proposal regarding independent chair policy

 

If you plan to attend the Annual Meeting, please bring this admission ticket with you.

 

 

  Here’s how to order a copy of the proxy materials and select a future delivery preference:
  
 Paper copies: Current and future paper delivery requests can be submitted via the telephone, Internet or email options below.
  
 Email copies: Current and future email delivery requests must be submitted via the Internet following the instructions below. If you request an email copy of the current materials you will receive an email with a link to the materials.
   
  PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a set of proxy materials.
   
    Internet - Go to www.investorvote.com/PFE and follow the instructions to log in and request a copy of the current meeting materials and submit your preference for email or paper delivery of future meeting materials.
   
    Telephone - Call at 1-866-641-4276 or +1-781-575-4581 for outside the USA, US territories and Canada and follow the instructions to log in and request a paper copy of the materials by mail for the current meeting. You can also submit a preference to receive paper copies for future meetings.
   
    Email - Send an email to investorvote@computershare.com with “Proxy Materials Pfizer Inc.” in the subject line. Include in the message your full name and address, plus the number located in the shaded bar on the reverse side, and state in the email that you want a paper copy of the current meeting materials. You can also state your preference to receive paper copies for future meetings.
   
    To facilitate timely delivery, all requests for paper copies of proxy materials must be received by April 18, 2017.
     
  02IDOG
 
GRAPHIC 2 x2_c87736x1x1.jpg GRAPHIC begin 644 x2_c87736x1x1.jpg M_]C_X 02D9)1@ ! 0 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MKSWQA\7] \,,]K:DZIJ(X,-NXV(?]M^@^@R: /0JYS7O'?ACPV2FIZO;QS#_ M )8(V^3_ +Y7)'XU\Z>(_BCXJ\2,R27[6-J?^7>R)C&/=OO'\Q7&!57[H SZ M4#L>]ZK^T%I\3[-'T*YNQ_STNI1 OX !B?Q KC=0^./C&\XMVL+!?^F-N7/Y MN3_(5SGAGP)KWBN&6ZL((H;"+/F7MT_EQ+CK@]\=\<>];%A\*[[6X;E] \0: M)J[VY EC@D=2,YQR1CG'_P!>@#*N?B/XTNB_F>);Y0^Z@;9)$XY4_U^M5Z -7_A)_$7 M_0PZS_X,9O\ XJM6W^)?C:VD#KXDO'YSB4(X_5:Y6B@9ZEI7QX\3V;@:C9V& MHQ]\ P/_ -]#(_\ ':]#\/\ QN\+:NRQ7[3:1.>,70!CS[2#C\\5\U44"L?; MLM^"KD'3YO-LR?WEC,Q\IOI_\*>*],\8:*FHZ;)Q]V6%OOPOW5A_7O0(W**** "BBB@ HHHH **** "BBB@ M HHHH **** "JFIZG9:/ITVH:C4Q%YKHN3@-AEV#"DX![C/7CE[KX/Z3IU\=.NOB#I- MM=J ?(FM0A&1D<&;O7H/P,TG[!X ^VL,2:C43R#$ORIU[;0#^- SH/%7PH\2>%;%]0D^SW]@@W236A;,8 M]60C./<$^^*Q/!GAM_%OBNQT<,R0RL7N)$ZK$O+$>YX /J17T9\*8+@?##1X M[XF3?"Q59#N_=%CM7GMMP,>E&O#,&K0ZQ/)Y[+0[^YLK>"."&1(_E/5F(_X M$Q_*N"NO!/BBRM9;JZT"^@MXE+R2R1X55'4DYH M_$3Q+:>+/&=UJEC$R6I1 M(8V==K2!1C<1VSVSSC%ECCU?3;BS,F?+,J_*^.N". M#4NF>%?$&M6GVK3-&O+NWW%/,B3*[AU% &176?#CQ5+X2\8VMP9"+*Z9;>[3 M/!4G 8^ZDY_/UK'T[PUKFK7UU9:?I-UHVDUI=QIN,3.]H$+9]=HS5J@04 M444 %%%% !1110 4444 %%%% !1110!XA\>?%CI]E\*VDI42*+F^VGJN?W:? MB06(]E]:\.VNY"1KND$ 'HL9V#]%_6 MK/PTTC^VOB'H]NPS'%+]ID&,C;&,_P \4#/I0:/:\6TGX-V5G(DWB?Q3I<5C'C?#;3?,V.JEVQC\!FNJ^/^L-:^ M']*TF)W5[VY:9]IQE(@.,]?O.GY&OGWRTZ[1GZ4 CWOQ]\6]'L]"ET'PK(LT M\D7D?:(5Q%;IC!VGN<<#' ZUUGPKT^/P_P#"W37N"(5DA:]E9CPH?+9/_ <5 M\PV-A)JFHVFG0Y\R[F2!<#D;B 3^ )/X5]._%2^CT'X6ZC#;@Q"6)+&%8\#: M&(7'TVYH \:T/Q]XV\2>*[&SAUVZ@2_O!^[C"D11LVX@9'15X_"O6?C;J_\ M9OP^EM59? W2?[0\>/>LH,>GVS29(S\[_*OT.-U M:GQYU"74/%6CZ';*\TD,1<1(N6:25@J@>IPOZT <5X;\4>-=UEX?\.ZE=98E M+>UB5<#)R221P.223TKWFZU\_#3P5'-XGU>75M5D)*+P&FDP/D08&$'J?J>N M*S_#?A>U^%'@VXU62PEU37)(U$PM4+N[$\11\<(">3CG&2.@KQ3Q"GC/Q3J\ MFJ:OI.IR3L,*HM) D*==J#' _GU- '=?#7PI)\0M>OO&7B@)=0"?;' PRDL@ MZ@J?X%&T =^<^]3QKXZ\5>+/%<^A^$C?1V=M(8(UL@4:9E."S/V7(..0,#-> ME?"&2.3X6Z<+1HS(@E5O02;CU_2O';WXJ>/UO)-,>1+"_$FV2WM[%1+N&?EP M02?6@1WWQ:OTTCX5Z?HFLW:W>MS+%E^K%DP7D^G49XSFNR\!V,7A3X9Z?]LQ M (K4W5RQ'W2078G'7']*^>YO"?B2Y\8Z+8^(XKLWFKO&V^YD,DACW8;<><$ M M&$+)]@C4&0J<_O78\O*3\S'//2G>*M8@^*_Q)TFVTJUDBMR%MM\RX=T#;W9A MV &<#Z^M><$@ DG ')KZ$^"O@231[%_$FIP[+V\C"VL3CF*$\[O9FX_ #U- MSUM55%"J,*!@ =A2T44""BBB@ HHHH **** "BBB@ HHHH **** /DSXF:-) MHGQ#U>%]Q2YF-Y$Q'59"6_1MP_"JO@WQA=^"M4GU"RL[:YGEA\D?:-V$&[_%KP!)XOTB*]TV-3J]B&\M3@>?&>3'GUR,KGOGU-?,[*R.T;JR.A M*NCC#*1U!'8T#.@\9>,;_P ;:M#J&H0P0O#"(4C@SM R23R>I)_05SO:EHH& M=[\&])&J?$>SD= T=C$]TV1P"/E7\KI^GV<[WC(TDDY?.%!P!@XQ\Q/XU7E\;7L_CU?%\U MG:RWB.)%@;=Y2D+M&.<\=>O6N:HH ]8_X: \1_\ 0(TK_P B?_%5#=_'CQ'= M6<]N--TV(RQLGF)YFY,C&1\W45Y;10%CI?!OCO6O \KC3)$EM),&6TG&8V(& M-PQRK8[CKW!XKM[WX_:M+"/L>@V%O<;"#-)*TN#Z@87WX)->1T4!8Z:P\=ZS M;>,(_$]\Z:IJ$:LJ"Z)V(""/E"XV@9. /4U+XW^(6I^.!8_VC;VULEF7*+;E ML,6QR++GR=&L6F4??G?Y8D^K_P!!DU] >!OA'I/A4QWU M_LU+5EY$KK^[A/\ L*>_^T>?I0!Q_P ,?A%++-%KOBFU"PKA[73Y1RQ_O2J> M@Z$+^?I7NU%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X'QS\*M( M\8.;V%O[/U7'-S$N5E]!(O?Z\'WK0N?B=X/M+RXM)M8 GMY6AE46\K;74X(R M%QP:B_X6MX+_ .@P?_ 2;_XB@#YZ\1?#SQ1X7=C?Z9)+;@\75H#+$WOP,KU_ MB _&N6WJ5+!@5'4@]*^KO^%K>"_^@R?_ $F_P#B*YW6M9^$'B$-_:<5G+(Q MRTR6,T^'UG'X5^%EE+<(5V6K7LXQSD@N?TXKY:GNIKZY MFO;AMT]S(TTC8QEF.3^IKZ5UGQSX"UGPY/+T'MNTQR/_0: /.Z*]#3P?\/^=_CV[/IMTN0?S6K]KX6^%48' MVKQ;JDYQSLMGC!/_ 'Z- 7/+:=!')=2^3;Q23R_W(D+M^0YKW+3[;X)Z>Z28 M^U2(<[KN*YF!^J,-OZ5UUC\0_AWID*PZ?=V]I$HP$M]/DC4?@$H"YXKH?PC\ M8ZVP9M.&FP=YK]MA_!!EB?J />O4_#?P,T#3"D^LS2:M.O/EN-D /^X.6_$D M>U=#_P +6\%_]!@_^ DW_P 11_PM;P7_ -!D_P#@)-_\10(ZVUM+>QMDMK2" M*"!!A(XD"JH]@*FKC/\ A:W@O_H,G_P$F_\ B*7_ (6MX+_Z#)_\!)O_ (B@ M#LJ*XS_A:W@O_H,'_P !)O\ XBE_X6MX+_Z#!_\ 2;_ .(H [*BN-_X6MX+ M_P"@P?\ P$F_^(I/^%K>"_\ H,G_ ,!)O_B* .SHKC/^%K>"_P#H,G_P$F_^ M(H_X6MX+_P"@P?\ P$F_^(H [.BN,_X6MX+_ .@P?_ 2;_XBC_A:W@O_ *#) M_P# 2;_XB@#LZ*XW_A:W@O\ Z#)_\!)O_B*3_A:W@O\ Z#)_\!)O_B* .SHK MC?\ A:W@O_H,'_P$F_\ B*/^%K>"_P#H,'_P$F_^(H [*BN-_P"%K>"_^@P? M_ 2;_P"(I/\ A:W@O_H,'_P$F_\ B* .SHKD;?XG^#[JZ@MH=7W33RI%&IMI M1N=B%49*XY)%% &7\+E5I/&>Y0?^*DN^H]DK0\5>/-.\+7-Q!+I\UT\%O'.X MBVC[[E5'/?"N?HM8?PXU?3=/N/&,=[J-I;.WB.[95FF5"1\O.":GUK1_#>MZ MG?WLWBVQ4W8"[!+$0@6)XU ^;L9&;ZF@"]>?$33K?4=2LK?39+A[*>WM@X=$ M6669F4*"3P 4;)/]TTMKX]CU 1VVGZ#/YESMVY=0".I M)'8UDV?ACP=;&U27Q)I]U;P7,=P\4TT3><8X#&H.6STB6<_8WN[A) M)HH6@".493O(RVY6'&>E78?&IN=O#3+KR+*X6 M)(B@$EPKA2CHOHRN",\XJ34O'EG:6.I7UGI4M_:Z>8?-DB=%W"1 ZE=QY^\H MQUR:S+?P_P"$+/47FMO$UJMJUU;77V:2]64;H5=0-S,3@[EX[; *;9>'_"=A MX=;1(?%%G]F?4DOF+7$9.U75EB^]]T;5'T% '676MG3?#K:GJ.DO!<;A''9* MZ222R,VU$4KP2Q(^F>>E9B>/M'=O# ^SN!X@C9X6P,0X"\/_ ,"8+]:371X8 M\17]A)?^([3[)9EY$MX;X1%IC@+(75P?E&X #^\?:N?_ .$5\*'2I-/;Q;:F M(6#6-J?M$8-N#,90X.[)8'8/?8/6@#1C^*6BM%5IC:D@8*?-0$_( M#_>(VG'HU:TOC&SBMKZ4Z=(6M=2ATP("O[R:3RQP>F 9,'_=-);(;+NWN%87$8PD2*GE_>^ZP4Y^OM5B32=&-]/)%XYM$M3>2ZC;VQ>%A%= M.#ARQ.7568L%/&<>@H WE\::6VKZQ9&UD6+3+=[A[EE CE"<2!/7:< ^];%G MJ5O/X>AUBXM_LD3VHN9$D +1+MW$''H*\^D\(>#H[)[;3_%D-MYVGS6,[R7R MS&42%2SX9\*258G& 2Q]!6T[6-UX6U/1;_QS87'VR%H$F3R8C#&R[2 JG!XS M0 RP^)>F7RZ(/[+GBDU-I=R.4_T5$)!:3GH=K8]=K>AJ"W^)MK-H,FLMHJK: MB&.50M[ SDR,%164-E,Y_BQC!JA-X6\,/-J,D7C"SB-\]T[ 2Q'9YL9C0+\W M C$DV!W,K&AO#^D2:8MDWC;1P(YH98FCM;9 /*SA6 /SCIU]* -NY\<2VVCI MJ1\.^=$]TMJ!;WUO+\[%57D-CEFQCMC)I)_B'8V,JQ:CI4MLW]H1:=+\Z.(I M'C\QB2#]U04R?]KV-1QVVA-I^F6MUXKTN3[%J"WS&(00K*5!VJ54X&"0<]>* MJ/H'A*ZNIYK[Q+8W"W#7S2I]HC7<;D(N?O=42,*#^- &L_C>"68VVG:-->7? MFW"^7OCC58X7\MI&=CA07RH'4X-:$WB2W@T/3M2DTV>-[ZYAMDMI%59$>1PG M/...3P>@KD/^$)[*&'1G$D)-Q$Q=Q&R*6Y X+[O/%GL8ICH3&>YDCBL[:"ZAF>:1E+;3M;";5&2 M6QBN>N/!7@^6&*./Q7:1*NDQZ8X6XCP^W:#+C=PS("A]C[5T&KVWA>\-G/I7 MB#2M(O;.83M*[70CUW4EI\2='N;C3(I+*2 7D$\TLC[2ENL189+#A@3&^"N00N:S MD\-^#9IS)JGB.QU(2V]REQY\\0,LLY3?+D'Y2%154 #:!Q4$GAGPW>&S.H^, M;.Y\@6:L!)$@D2W64;" W1S,2P]J -:/XDZ:VAZ9J3Z1=QF_N#&L!5=\48<( M97[!064>N3BK&I>-6TO5-5M9O#LQATRU-Y<7"SQ;1#A]IQG.6\ML+UKG'\'^ M$[C3IX;WQA#/>- L,-R+Q8_)PQ(%G\5V0. MM"WCF*SQY2*+^ ?-WR_/^U0!9N?'T5M#/=GP_>&QL?+74KC*#[+(X4E-N%/^A9T;_P (O\ XFBB@ _X0KPI M_P!"SHW_ ( 1?_$T?\(5X4_Z%G1O_ "+_P")HHH /^$*\*?]"SHW_@!%_P#$ MT?\ "%>%/^A9T;_P B_^)HHH D@\(>&;>YAF@\.Z1%+'(KHZ64:LK @@@A>" '#1110!__V0$! end GRAPHIC 3 x2_c87736x1x2.jpg GRAPHIC begin 644 x2_c87736x1x2.jpg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end